PDCD1 and cancer: In another study, it was reported that the response of peripheral blood PD-1+ CD8+ T cells, measured as the ratio in the percentage of Ki-67+ cells seven days after treatment, may predict the response and prognosis of cancer patients treated with anti-PD-1 therapy [66].